HER2 breast cancers (10 − 15% of breast cancers) overexpress HER2 receptors and can thus benefit from anti-HER2 antibodies, such as trastusumab, which block cell surface receptor dimerization with other family members and the activation of downstream signaling pathways. Here, ERBB2 is linked to breast cancer.